Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pembrolizumab and Azacitidine for Relapsed/Refractory Hodgkin's Lymphoma
NCT05355051Phase 2Recruiting
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Oct 2022
- Primary completion
- Dec 2026
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of pembrolizumab and azacitidine in Hodgkin lymphoma (HL) and acute myeloid leukemia (AML), sponsored by University of Texas MD Anderson Cancer Center. Primary endpoint: Overall Response Rate at 1 year. Started Oct 2022; status: recruiting.
02
Drugs
pembrolizumabazacitidine
03
Conditions
Hodgkin lymphoma (HL)acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT05355051.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05355051.